Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

The Swedish BioFINDER - Preclinical AD Study

Authors not listed

Skane University Hospital · 2022

Abstract

This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population. This observational study will take place at the Skåne University Hospital in Sweden. The study will enroll up to 600 cognitively healthy subjects aged 50 to 80 years with 3/4 having preclinical Alzheimer's disease. Recruitment and enrollment will be ongoing for 2-3 years, and subject participation will be lasting approximately 4 years. Disclosure of AD risk assessments will be an optional procedure.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-11 MST

Cite this

APA
Anonymous. (2022). The Swedish BioFINDER - Preclinical AD Study. <em>Skane University Hospital</em>. https://clinicaltrials.gov/study/NCT06121544
Vancouver
Anonymous. The Swedish BioFINDER - Preclinical AD Study. Skane University Hospital. 2022.
BibTeX
@misc{anon2022TheSwe, title = {The Swedish BioFINDER - Preclinical AD Study}, author = {Anonymous}, journal = {Skane University Hospital}, year = {2022}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings